BioMarin Pharmaceutical Inc. (BMRN) financial statements (2022 and earlier)

Company profile

Business Address 105 DIGITAL DRIVE
NOVATO, CA 94949
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments1,0141,0791,1231,0871,0651,5061,380
Cash and cash equivalents5876176426676491,016819
Short-term investments427462482420416490561
Receivables373375424396448412381
Inventory, net of allowances, customer advances and progress billings777749711714699701744
Inventory777749711714699701744
Other current assets1101089991130121142
Total current assets:2,2742,3122,3582,2892,3422,7392,648
Noncurrent Assets
Property, plant and equipment1,0351,0251,0271,0221,0321,0151,011
Long-term investments and receivables508467350321285265323
Long-term investments508467350321285265323
Intangible assets, net (including goodwill)585585590602613623630
Goodwill196196196196196196196
Intangible assets, net (excluding goodwill)389388394406417427433
Deferred income tax assets1,4491,4451,4321,4291,4321,397555
Other noncurrent assets152145142141142119136
Total noncurrent assets:3,7293,6663,5413,5163,5063,4192,655
TOTAL ASSETS:6,0035,9775,8985,8055,8486,1585,302
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:492467411399493480443
Accrued liabilities15151718172021
Employee-related liabilities204158130118165137115
Taxes payable21211078
Other undisclosed accounts payable and accrued liabilities270293263262301315300
Debt     374370
Business combination, contingent consideration, liability48483231   
Total current liabilities:540515443430493855813
Noncurrent Liabilities
Long-term debt and lease obligation1,0791,0781,0771,0761,0751,0741,073
Long-term debt, excluding current maturities1,0791,0781,0771,0761,0751,0741,073
Liabilities, other than long-term debt114118136137174175179
Other liabilities99103106108114121129
Business combination, contingent consideration, liability15153129605450
Total noncurrent liabilities:1,1931,1961,2141,2131,2491,2501,252
Total liabilities:1,7331,7111,6571,6431,7422,1042,065
Stockholders' equity
Stockholders' equity attributable to parent, including:4,2714,2664,2424,1624,1064,0543,237
Common stock0000000
Additional paid in capital5,1925,1345,0845,0114,9934,9384,886
Accumulated other comprehensive income (loss)1410(1)5(16)1030
Accumulated deficit(926)(868)(831)(844)(862)(884)(1,669)
Other undisclosed stockholders' equity attributable to parent(10)(10)(10)(10)(10)(11)(11)
Total stockholders' equity:4,2714,2664,2424,1624,1064,0543,237
TOTAL LIABILITIES AND EQUITY:6,0035,9775,8985,8055,8486,1585,302

Income statement (P&L) ($ in millions)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues450409502486452477429
Cost of revenue(120)(104)(127)(120)(126)(189)(98)
Gross profit:330305375366326288332
Operating expenses(379)(341)(345)(323)(352)(327)(358)
Other undisclosed operating loss(17)(17)(18)(18)(19)(17)(15)
Operating income (loss):(66)(53)1225(45)(56)(41)
Nonoperating income (expense)2242(5)44
Investment income, nonoperating2242344
Foreign currency transaction loss, before tax    (8)  
Interest and debt expense(4)(4)(4)(4)(5)(10)(8)
Income (loss) from continuing operations before equity method investments, income taxes:(68)(55)1224(55)(62)(45)
Income (loss) from equity method investments 0(0)(1)1(1)(0)
Other undisclosed income from continuing operations before income taxes19211313
Income (loss) from continuing operations before income taxes:(67)(46)1423(40)(61)(42)
Income tax expense (benefit)910(1)(6)6284613
Net income (loss) available to common stockholders, basic:(58)(36)131722785(29)
Interest on convertible debt    (10)7 
Net income (loss) available to common stockholders, diluted:(58)(36)131712792(29)

Comprehensive Income ($ in millions)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net income (loss):(58)(36)131722785(29)
Other undisclosed comprehensive income (loss)31   (36)  
Comprehensive income (loss):(27)(36)1317(14)785(29)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(26)11(6)2110(20)(4)
Comprehensive income (loss), net of tax, attributable to parent:(54)(25)739(4)765(33)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: